Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | EED | O75530 | 1/20 | 0.62 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.62 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.62 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.62 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22561459 | 0.94 | EZH2 (0.70) | EZH2CYP2D6CYP2C19EEDRBBP4 | |
| SCHEMBL13279610 | 0.93 | EZH2 (0.85) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL15710365 | 0.92 | EZH2 (0.74) | EZH2CYP2D6CYP2C19EEDRBBP4 | |
| SCHEMBL13468077 | 0.92 | EZH2 (0.86) | EZH2CYP2D6CYP2C19EEDRBBP4 | |
| SCHEMBL17148709 | 0.91 | EZH2 (0.72) | EZH2CYP2D6CYP2C19EEDRBBP4 | |
| SCHEMBL21862648 | 0.91 | EZH2 (0.88) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL17136212 | 0.91 | EZH2 (0.74) | EZH2CYP2D6CYP2C19EZH1 | |
| SCHEMBL13280391 | 0.91 | EZH2 (0.71) | EZH2CYP2D6CYP2C19EEDRBBP4 | |
| SCHEMBL15700593 | 0.91 | EZH2 (0.74) | EZH2CYP2D6CYP2C19EZH1 | |
| SCHEMBL22561570 | 0.89 | EZH2 (0.84) | EZH2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.